Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.
Journal of Clinical Oncology (2014)
  • John Francis Seymour, Peter MacCallum Cancer Centre
  • Matthew Steven Davids, Harvard University
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Brad S. Kahl, University of Wisconsin-Madison
  • William G. Wierda, University of Texas MD Anderson Cancer Center
  • Soham Puvvada, University of Arizona
  • John F. Gerecitano, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, Ghent University
  • Mary Ann Anderson, Walter and Eliza Hall Institute of Medical Research
  • David C.S. Huang, University of Melbourne
  • Nikita Rudersdorf
  • Lori A. Gressick
  • Nicholas P. Montalvo
  • Jianning Yang
  • Ming Zhu
  • Martin Dunbar
  • Elisa Cerri, University of Chicago
  • Sari H. Enschede, Rush University Medical Center
  • Rod Humerickhouse, Roswell Park Cancer Institute
  • Andrew Warwick Roberts, University of Melbourne
Link
Disciplines
Publication Date
May 20, 2014
Citation Information
John Francis Seymour, Matthew Steven Davids, John M. Pagel, Brad S. Kahl, et al.. "ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control." Journal of Clinical Oncology Vol. 32 (2014) p. 7015
Available at: http://works.bepress.com/john-pagel/95/